Menu
Search
|

Menu

Close
X

Titan Pharmaceuticals Inc TTNP.OQ (NASDAQ Stock Exchange Capital Market)

0.87 USD
-0.03 (-3.33%)
As of 3:10 PM BST
chart
Previous Close 0.90
Open 0.87
Volume 1,291
3m Avg Volume 16,737
Today’s High 0.87
Today’s Low 0.87
52 Week High 2.80
52 Week Low 0.60
Shares Outstanding (mil) 21.20
Market Capitalization (mil) 50.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
0
FY16
15
FY15
2
EPS (USD)
FY18
-0.123
FY17
-0.675
FY16
0.220
FY15
-0.563
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
285.89
5.73
Price to Book (MRQ)
vs sector
6.75
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-85.18
14.61
Return on Equity (TTM)
vs sector
-90.44
16.34

EXECUTIVE LEADERSHIP

Marc Rubin
Executive Chairman of the Board, Since 2009
Salary: $210,000.00
Bonus: --
Sunil Bhonsle
President, Director, Since 2009
Salary: $300,000.00
Bonus: --
Seghi Recli
Lead Director, Since 2018
Salary: --
Bonus: --
Rajinder Kumar
Director, Since 2017
Salary: --
Bonus: --
Federico Seghi Recli
Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

400 Oyster Point Blvd Ste 505
SOUTH SAN FRANCISCO   CA   94080-1958

Phone: +1650.2444990

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

SPONSORED STORIES